RecruitingPhase 4NCT06978439

Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

Studying Kawasaki disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Children's Hospital of Fudan University
Principal Investigator
Fang Liu, MD
Children's Hospital of Fudan University
Intervention
Rivaroxaban (Xarelto)(drug)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
20242025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06978439 on ClinicalTrials.gov

Other trials for Kawasaki disease

Additional recruiting or active studies for the same condition.

See all trials for Kawasaki disease

← Back to all trials